|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-5-22
|
|
pubmed:abstractText |
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily and are key regulators of fatty acid oxidation (FAO) in the heart. Systemic carnitine deficiency (SCD) causes disorders of FAO and induces hypertrophic cardiomyopathy with lipid accumulation. We hypothesized that activation of PPARalpha by fenofibrate, a PPARalpha agonist, in addition to conventional L-carnitine supplementation may exert beneficial effects on the lipotoxic cardiomyopathy in juvenile visceral steatosis (JVS) mouse, a murine model of SCD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1,2-diacylglycerol,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Triphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Carnitine,
http://linkedlifedata.com/resource/pubmed/chemical/Diglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Fenofibrate,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Peroxisome Proliferator-Activated...,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-6363
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
566-77
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16546150-Adenosine Triphosphate,
pubmed-meshheading:16546150-Animals,
pubmed-meshheading:16546150-Cardiomyopathy, Hypertrophic,
pubmed-meshheading:16546150-Carnitine,
pubmed-meshheading:16546150-Diglycerides,
pubmed-meshheading:16546150-Drug Therapy, Combination,
pubmed-meshheading:16546150-Echocardiography,
pubmed-meshheading:16546150-Fatty Acids,
pubmed-meshheading:16546150-Fatty Liver,
pubmed-meshheading:16546150-Fenofibrate,
pubmed-meshheading:16546150-Mice,
pubmed-meshheading:16546150-Mice, Inbred C3H,
pubmed-meshheading:16546150-Mice, Mutant Strains,
pubmed-meshheading:16546150-Models, Animal,
pubmed-meshheading:16546150-Myocardium,
pubmed-meshheading:16546150-PPAR alpha,
pubmed-meshheading:16546150-Peroxisome Proliferator-Activated Receptors,
pubmed-meshheading:16546150-Protein Kinase C,
pubmed-meshheading:16546150-Random Allocation,
pubmed-meshheading:16546150-Treatment Outcome,
pubmed-meshheading:16546150-Triglycerides
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
|
|
pubmed:affiliation |
Department of Cardiology, Nagoya University Graduate School of Medicine, Showa-ku, Japan.
|
|
pubmed:publicationType |
Journal Article
|
